GlassScriptPhysician profile
Raymond N Englander
NPI 1316018898
$2,128.64
in general payments reported to CMS, 2019-2025
24 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $47.53 · 2021: $353 · 2022: $137 · 2023: $344 · 2024: $125 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $706.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $180.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $146.97 | 2021-2025 | |
| Boston Scientific Corporation | $142.21 | 2023 | Watchman Access System |
| Abbvie INC. | $135.95 | 2022-2025 | |
| Genentech USA, INC. | $128.01 | 2019 | |
| Eisai INC. | $115.90 | 2025 | |
| Argenx US, INC. | $84.64 | 2023 | Vyvgart |
| Jazz Pharmaceuticals INC. | $71.11 | 2022 | |
| Acorda Therapeutics, INC | $61.52 | 2019-2023 | Inbrija, Ampyra |
| Biohaven Pharmaceuticals, INC. | $60.27 | 2021 | |
| Allergan, INC. | $33.99 | 2020-2021 | |
| Emd Serono, INC. | $33.09 | 2019-2022 | |
| Cala Health, INC. | $29.71 | 2023 | Cala Trio |
| Lundbeck LLC | $28.15 | 2024 | Vyepti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $27.39 | 2024 | Xeomin |
| Nalu Medical, INC. | $24.51 | 2023 | Nalu Neurostimulation System |
| Sunovion Pharmaceuticals INC. | $21.36 | 2020 | |
| Lilly USA, LLC | $19.61 | 2025 | Kisunla |
| Zogenix INC. | $19.40 | 2021 | |
| Impel Pharmaceuticals INC. | $17.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.07 | 2019 | |
| Biogen, INC. | $13.11 | 2020 | |
| Alnylam Pharmaceuticals INC. | $13.01 | 2023 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Englander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.